| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/31/2006 | US20060195917 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype |
| 08/31/2006 | US20060194970 Process for producing imide compound |
| 08/31/2006 | US20060194966 N'-{2-amino-1-(3,5-difluorobenzyl)-3-[(3-; ethylbenzyl)oxy]propyl}-N,N-dipropylisophthalamide; beta-secretase inhibitors; halts or reduces production of A beta peptide from amyloid precursor proteins and reduces or eliminates the formation of beta-amyloid deposits in the brain |
| 08/31/2006 | US20060194872 Diamine derivative, production process therefor and antioxidant |
| 08/31/2006 | US20060194864 Indole derivatives |
| 08/31/2006 | US20060194863 e.g. [(4-Morpholinophenylamino)-methylene]-1,3-dihydro-indol-2-one;tyrosine kinase signal transduction modulators; antiproliferative agents; vision defects, atherosclerosis, restenosis, metabolic disorders, autoimmune diseases |
| 08/31/2006 | US20060194860 Pharmaceutical compositions containing aryl or heteroaryl azolylcarbinol compounds |
| 08/31/2006 | US20060194855 Method of treating migraines and pharmaceutical compositions |
| 08/31/2006 | US20060194854 New 2-substituted - 1,3-thiazole compounds |
| 08/31/2006 | US20060194850 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 08/31/2006 | US20060194843 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide |
| 08/31/2006 | US20060194841 Benzylamine derivative |
| 08/31/2006 | US20060194834 Serotonin receptor antagonist; psychological disorders; Alzheimer's disease |
| 08/31/2006 | US20060194830 Cyclizing 2,6-diaminopyridine in sulfuric acid with malic acid to form 2-amino-7-hydroxy-1,8-naphthyridine; phthalimidating the naphthyridine and replacing the OH with Cl; reducing the product to form the hydroxyindolinone derivative and etherifying with 5-methyl-2-oxo-hexyltriphenylphosphonium halide |
| 08/31/2006 | US20060194825 Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| 08/31/2006 | US20060194818 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194817 N-{(1S,2R)-1-(3,5-difluorobonzyl)-2-hydroxy-3-[(3-iodobonzyl)amino]propyl}-2-{4-[(methylsulfonyl)amino]phenyl}acetamide; inhibitors of the beta- secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mamma |
| 08/31/2006 | US20060194815 Methods and compositions for modulating serum cortisol levels |
| 08/31/2006 | US20060194806 Optically active 5H-pyrrolo [3,4-b] pyrazine derivative, its preparation and pharmaceutical compositions containing same |
| 08/31/2006 | US20060194803 anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient; to improve learning disorder |
| 08/31/2006 | US20060194793 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/31/2006 | US20060194792 1-Cyclic carbonyl-4-(4-quinoline-)-1,4-diazepine or 1-cyclic carbonyl-4-[4-(1H-quinolin-2-{thio}one)-1,4-diazepinone derivatives; retinopathy, adult respiratory distress syndrome, asthma, osteoarthritis, glomerulonephritis, psoriasis, rheumatoid arthritis, and toxic shock syndrome treatment |
| 08/31/2006 | US20060194791 Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 08/31/2006 | US20060194785 Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof |
| 08/31/2006 | US20060194781 Alkyl ether derivatives or salts thereof |
| 08/31/2006 | US20060194778 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 08/31/2006 | US20060194777 Compositions and methods using same for treating amyloid-associated diseases |
| 08/31/2006 | US20060194766 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 08/31/2006 | US20060194745 Compounds and methods for inhibiting selectin-mediated function |
| 08/31/2006 | US20060194337 Characterizing the existence of a disease state; particularly to the utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state |
| 08/31/2006 | US20060193929 Method for treating or preventing symptoms associated with menopause |
| 08/31/2006 | US20060193871 transmission and, or amplification of signal; oral or enteric administering, dissolving, absorption; peptide yy; obesity therapy |
| 08/31/2006 | US20060193823 Hydrolytically degradable carbamate derivatives of poly (Ethylene Glycol) |
| 08/31/2006 | DE102005009217A1 New phosphoric acid salts of 6-dimethylaminomethyl -1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane useful to treat e.g. pain, migraine, depressions, neurodegenerative illnesses, cognitive illnesses, fear conditions and epilepsy |
| 08/31/2006 | CA2768075A1 Dosage form containing oxycodone and naloxone |
| 08/31/2006 | CA2614731A1 Multimediator dopamine transport inhibitors, and uses related thereto |
| 08/31/2006 | CA2601935A1 Nk1 antagonists |
| 08/31/2006 | CA2599295A1 Method of producing proanthocyanidin oligomer |
| 08/31/2006 | CA2599291A1 Compounds for reducing aggregation of amyloid beta-peptide |
| 08/31/2006 | CA2599151A1 Novel quinoline derivatives as potassium ion channel openers |
| 08/31/2006 | CA2598853A1 Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists |
| 08/31/2006 | CA2598838A1 Multimediator 5-ht6 receptor antagonists, and uses related thereto |
| 08/31/2006 | CA2598517A1 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease |
| 08/31/2006 | CA2598278A1 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| 08/31/2006 | CA2593750A1 Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
| 08/30/2006 | EP1695985A2 Humanized antibodies and methods for forming humanized antibodies |
| 08/30/2006 | EP1695982A1 Glycosylation-deficient hepatocyte growth factor |
| 08/30/2006 | EP1695977A2 Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines |
| 08/30/2006 | EP1695974A1 1,8-Naphthyridines as CRF antagonists |
| 08/30/2006 | EP1695970A1 Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 08/30/2006 | EP1695703A2 Anticonvulsant amino acids for the treatment of pain |
| 08/30/2006 | EP1695700A1 Dosage form containing oxycodone and naloxone |
| 08/30/2006 | EP1695061A2 Method for treating neurological disorders |
| 08/30/2006 | EP1694701A2 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders |
| 08/30/2006 | EP1694688A1 Vanadium compounds as inhibitors of phosphatases |
| 08/30/2006 | EP1694673A1 Novel thiazole derivates |
| 08/30/2006 | EP1694663A1 Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| 08/30/2006 | EP1694656A1 Benzoxazine derivatives and uses thereof |
| 08/30/2006 | EP1694654A2 Substituted triazoles as sodium channel blockers |
| 08/30/2006 | EP1694635A2 HYDROXYPROPYL AMIDES FOR THE TREATMENT OF ALZHEIMER’S DISEASE |
| 08/30/2006 | EP1694363A2 Pegylated small molecules |
| 08/30/2006 | EP1694353A2 Composition and methods for modulating cns activity |
| 08/30/2006 | EP1694344A1 Methods and composition for transplantation of dopaminergic neurons for parkinson s disease |
| 08/30/2006 | EP1694334A1 Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| 08/30/2006 | EP1694318A1 (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist |
| 08/30/2006 | EP1694317A1 Copper antagonist compounds |
| 08/30/2006 | EP1694316A1 Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality |
| 08/30/2006 | EP1694313A2 Tellurium derivatives for prevention and treatment of neurodegenerative processes |
| 08/30/2006 | EP1646328A4 Treatment of dependence withdrawal |
| 08/30/2006 | EP1513837B1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 08/30/2006 | EP1490056B1 N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases |
| 08/30/2006 | EP1442030B1 Thiopene- amd thiazolesulfonamides as antineoplastic agents |
| 08/30/2006 | EP1436292B1 5-methoxy-8-aryl-¬1,2,4|triazolo¬1,5-a|pyridine derivatives as adenosine receptor antagonists |
| 08/30/2006 | EP1425280B1 Hetero-bicyclic crf antagonists |
| 08/30/2006 | EP1421198A4 Cell-based high-throughput screening methods |
| 08/30/2006 | EP1421086B1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA a|NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |
| 08/30/2006 | EP1414810B1 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 08/30/2006 | EP1359914B1 Novel therapeutic use of a thienylcyclohexylamine derivative for treating pain |
| 08/30/2006 | EP1335722B1 Indolyl-sulfonyl- compounds useful in the treatment of cns disorders |
| 08/30/2006 | EP1333842B1 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 08/30/2006 | EP1266008B1 Acute neuronal induced calcium binding protein type 1 ligand |
| 08/30/2006 | EP1255724B1 Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament or a diagnostic reagent and medicaments containing said compounds |
| 08/30/2006 | EP1202953B1 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 08/30/2006 | EP1180524B1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
| 08/30/2006 | EP1066042B1 Steroidal saponins for treating alzheimer's disease |
| 08/30/2006 | EP1037900A4 Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies |
| 08/30/2006 | EP0909316B1 Glial cell line-derived neurotrophic factor receptor |
| 08/30/2006 | CN1826346A N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
| 08/30/2006 | CN1826338A Therapeutic agent for senile dementia |
| 08/30/2006 | CN1826336A Cyclohexanecarboxylic acid compound |
| 08/30/2006 | CN1826331A Pi-3 kinase inhibitor prodrugs |
| 08/30/2006 | CN1826323A 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
| 08/30/2006 | CN1824647A Crystal of (+-)2-(dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride |
| 08/30/2006 | CN1824297A Application of nerve growing factor in preparation of medicine for treating optic nerve affection |
| 08/30/2006 | CN1824296A Use of cone shell polypeptide derivative in preparation of drug abstaining medicine |
| 08/30/2006 | CN1824294A Preparation technology of sarcosine peptide glycoside injection liquid |
| 08/30/2006 | CN1824284A Medicine and food dual purpose Chinese medicinal product for spirit raising and brain arousing with no habituction and its manufacturing method |
| 08/30/2006 | CN1824283A Medicine and food dual purpose Chinese medicinal product for preventing and treating lethargy and its manufacturing method |
| 08/30/2006 | CN1824275A Medicine and food dual purpose Chinese medicinal product for preventing and treating wind cold headache and its manufacturing method |
| 08/30/2006 | CN1824273A Medicine and food dual purpose Chinese mediicnal product for proventing and treating fright wind convulsion and its manufacturing method |